Funding for this research was provided by:
University of Texas MD Anderson Cancer Center (Prostate Moonshot Grant)
American Cancer Society (129098-RSG-16-092-01-TBG)
National Cancer Institute (RO1CA240526)
Received: 3 January 2020
Accepted: 13 May 2020
First Online: 6 July 2020
Ethics approval and consent to participate
: All patients in this study were treated for prostate cancer at the University of Texas MD Anderson Cancer Center (Houston, TX) and provided informed consent per an Institutional Review Board-approved prospective protocol. Two patient cohorts that were included in this study are (i) newly diagnosed metastatic and hormone-naïve (CSPC) (including patients participating in clinical trials NCT01409200 or NCT01630590) and (ii) CRPC (including patients participating in clinical trial NCT01505868). The patient sample collection was approved by the Institutional Review Board under protocol PA13-0247. All the experimental methods comply with the Helsinki Declaration.
: All the samples in this study have been deintentified.
: The authors have no financial conflicts to declare.